Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Targeting sodium potassium pumps for the treatment of prion diseases

FY 2022-23

Summary
Targeting sodium potassium pumps for the treatment of prion diseases Prion diseases are rapidly progressing and fatal neurodegenerative diseases. This research aims to advance our understanding of these diseases and discover a treatment for them. We know that we could extend prion disease survival if we were able to reduce the levels of the cellular prion protein (PrPC). We also know that it would be safe to do so because individuals whose cells produce half the levels of PrPC are not impacted in their health, and animals who produce no PrPC are similarly unaffected. We recently discovered that PrPC binds to sodium-potassium ATPases (NKAs), transport proteins that use cellular energy to pump sodium and potassium ions in and out of cells. I hypothesize that targeting NKAs with their natural inhibitors, cardiac glycosides (CGs), may cause cells to internalize and degrade NKAs, and that PrPC residing next to NKAs may get co-degraded. In preparation of this proposal, I have validated this idea in several relevant human cell models. The group has also developed a synthetic CG that has favorable characteristics for brain applications. The current proposal is informed by these data and will address in independent, yet synergistic, aims the question: Can treatment with CGs reduce the levels of PrPC and extend prion disease survival? In collaboration with an international team, I will reveal in detail the mechanism of action through which CGs reduce PrPC levels and provide pre-clinical data for the treatment of prion diseases using this novel treatment modality. Moreover, the ability to suppress PrPC levels may translate into a treatment of Alzheimer’s disease (AD), because PrPC is widely believed to be a critical player in the demise of brain cells in AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486490
Name
Bel Ari
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting sodium potassium pumps for the treatment of prion diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Cardiac Glycoside; Kdc203; Prion Diseases; Prion Protein; Sodium Potassium Atpase; Treatment
Abstract
Targeting sodium potassium pumps for the treatment of prion diseases Prion diseases are rapidly progressing and fatal neurodegenerative diseases. This research aims to advance our understanding of these diseases and discover a treatment for them. We know that we could extend prion disease survival if we were able to reduce the levels of the cellular prion protein (PrPC). We also know that it would be safe to do so because individuals whose cells produce half the levels of PrPC are not impacted in their health, and animals who produce no PrPC are similarly unaffected. We recently discovered that PrPC binds to sodium-potassium ATPases (NKAs), transport proteins that use cellular energy to pump sodium and potassium ions in and out of cells. I hypothesize that targeting NKAs with their natural inhibitors, cardiac glycosides (CGs), may cause cells to internalize and degrade NKAs, and that PrPC residing next to NKAs may get co-degraded. In preparation of this proposal, I have validated this idea in several relevant human cell models. The group has also developed a synthetic CG that has favorable characteristics for brain applications. The current proposal is informed by these data and will address in independent, yet synergistic, aims the question: Can treatment with CGs reduce the levels of PrPC and extend prion disease survival? In collaboration with an international team, I will reveal in detail the mechanism of action through which CGs reduce PrPC levels and provide pre-clinical data for the treatment of prion diseases using this novel treatment modality. Moreover, the ability to suppress PrPC levels may translate into a treatment of Alzheimer’s disease (AD), because PrPC is widely believed to be a critical player in the demise of brain cells in AD.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bel, Ari
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~